Salinomycin kills cancer stem cells by sequestering iron in lysosomes

Nature Chemistry

Volumn 9, Issue 10, 2017, Pages 1025-1033

  Mai, Trang Thi ^a,b,c   Hamaï, Ahmed ^d   Hienzsch, Antje ^c,e   Cañeque, Tatiana ^a,b,c   Müller, Sebastian ^a,b   Wicinski, Julien ^f   Cabaud, Olivier ^f   Leroy, Christine ^d   David, Amandine ^d   Acevedo, Verónica ^a,b   Ryo, Akihide ^g   Ginestier, Christophe ^f   Birnbaum, Daniel ^f   Charafe Jauffret, Emmanuelle ^f   Codogno, Patrice ^d   Mehrpour, Maryam ^d   Rodriguez, Raphaël ^a,b,c  

^a INSTITUT CURIE   (France)

^b CNRS UMR3666   (France)

^c INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

^d INSTITUT NECKER ENFANTS MALADES   (France)

^e ABX Advanced Biochemical Compounds GmbH   (Germany)

^f AIX MARSEILLE UNIVERSITY   (France)

^g YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IRON; PYRAN DERIVATIVE; REACTIVE OXYGEN METABOLITE; SALINOMYCIN;

BREAST TUMOR; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CONFORMATION; DRUG EFFECT; DRUG SCREENING; FEMALE; HOMEOSTASIS; HUMAN; LYSOSOME; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HOMEOSTASIS; HUMANS; IRON; LYSOSOMES; MOLECULAR CONFORMATION; NEOPLASTIC STEM CELLS; PYRANS; REACTIVE OXYGEN SPECIES;

EID: 85021891297     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.2778     Document Type: Article

References (50)

1. Nieto, M. N., Huang, R. Y.-J., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21-45 (2016).
2. Tam, W. L. & Weinberg, R. A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 19, 1438-1449 (2013).
3. Pattabiraman, D. R. & Weinberg, R. A. Tackling the cancer stem cells-what challenges do they pose Nature Rev. Drug Discov. 13, 497-512 (2014).
4. Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007).
5. Quintana, E. et al. Efficient tumour formation by single melanoma cells. Nature 456, 593-598 (2008).
6. Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659 (2009).
7. Morel, A.-P. et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3, e2888 (2008).
8. Germain, A. R. et al. Identification of a selective small molecule inhibitor of breast cancer stem cells. Bioorg. Med. Chem. Lett. 22, 3571-3574 (2012).
9. Hartwell, K. A. et al. Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat. Chem. Biol. 9, 840-848 (2013).
10. Paulus, E. F., Kurz, M., Matter, H. & Vértesy, L. Solid-state and solution structure of the salinomycin-sodium complex: stabilization of different conformers for an ionophore in different environments. J. Am. Chem. Soc. 120, 8209-8221 (1998).
11. Lu, D. et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc. Natl Acad. Sci. USA 108, 13253-13257 (2011).
12. Yue, W. et al. Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance. Autophagy 9, 714-729 (2013).
13. Naujokat, C. & Steinhart, R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol. 2012, 950658 (2012).
14. Huczyski, A. et al. Antiproliferative activity of salinomycin and its derivatives. Bioorg. Med. Chem. Lett. 22, 7146-7150 (2012).
15. Borgström, B. et al. Synthetic modification of salinomycin: selective O-acylation and biological evaluation. Chem. Commun. 49, 9944-9946 (2013).
16. Huang, X. et al. Semisynthesis of SY-1 for investigation of breast cancer stem cell selectivity of C-ring-modified salinomycin analogues. ACS Chem. Biol. 9, 1587-1594 (2014).
17. Borgström, B., Huang, X., Chygorin, E., Oredsson, S. & Strand, D. Salinomycin hydroxamic acids: synthesis, structure, and biological activity of polyether ionophore hybrids. ACS Chem. Med. Lett. 7, 635-640 (2016).
18. Shi, Q. et al. Discovery of a 19F MRI sensitive salinomycin derivative with high cytotoxicity towards cancer cells. Chem. Commun. 52, 5136-5139 (2016).
19. Borgström, B., Huang, X., Hegardt, C., Oredsson, S. & Strand, D. Structure-activity relationships in salinomycin: cytotoxicity and phenotype selectivity of semi-synthetic derivatives. Chem. Eur. J. 23, 2077-2083 (2017).
20. Nishi, M. et al. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene 33, 643-652 (2014).
21. Minta, A. & Tsien, R. Y. Fluorescent indicators for cytosolic sodium. J. Biol. Chem. 264, 19449-19457 (1989).
22. Charafe-Jauffret, E. et al. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res. 73, 7290-7300 (2013).
23. Rodriguez, R. et al. Small-molecule-induced DNA damage identifies alternative DNA structures in human genes. Nat. Chem. Biol. 8, 301-310 (2012).
24. Larrieu, D., Britton, S., Demir, M., Rodriguez, R. & Jackson, S. P. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science 344, 527-532 (2014).
25. Abell, N. S., Mercado, M., Cañeque, T., Rodriguez, R. & Xhemalce, B. Click quantitative mass spectrometry identifies PIWIL3 as a mechanistic target of RNA interference activator enoxacin in cancer cells. J. Am. Chem. Soc. 139, 1400-1403 (2017).
26. Cañeque, T. et al. Synthesis of marmycin A and investigation into its cellular activity. Nat. Chem. 7, 744-751 (2015).
27. Pantopoulos, K., Porwal, S. K., Tartakoff, A. & Devireddy, L. Mechanisms of mammalian iron homeostasis. Biochemistry 51, 5705-5724 (2012).
28. Asano, T. et al. Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells. Mol. Cell Biol. 10, 2040-2052 (2011).
29. Hirayama, T., Okuda, K. & Nagasawa, H. A highly selective turn-on fluorescent probe for iron(II) to visualize labile iron in living cells. Chem. Sci. 4, 1250-1256 (2013).
30. Li, T. et al. Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells. Autophagy 9, 1057-1068 (2013).
31. Dixon, S. J. & Stockwell, B. R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10, 9-17 (2014).
32. Boya, P. & Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene 27, 6434-6451 (2008).
33. Aits, S. & Jäättelä, M. Lysosomal cell death at a glance. J. Cell Sci. 126, 1905-1912 (2013).
34. Galluzzi, L., Bravo-San Pedro, J. M. & Kroemer, G. Organelle-specific initiation of cell death. Nat. Cell. Biol. 16, 728-736 (2014).
35. Dixon, S. J. et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 (2012).
36. Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317-331 (2014).
37. Conrad, M., Angeli, J. P. F., Vandenabeele, P. & Stockwell, B. R. Regulated necrosis: disease relevance and therapeutic opportunities. Nat. Rev. Drug. Discov. 15, 348-366 (2016).
38. Yang, W. S. & Stockwell, B. R. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26, 165-176 (2016).
39. Cao, J. Y. & Dixon, S. J. Mechanisms of ferroptosis. Cell. Mol. Life Sci. 73, 2195-2209 (2016).
40. Torti, S. V. & Torti, F. M. Iron and cancer: more ore to be mined. Nat. Rev. Cancer 13, 342-355 (2013).
41. Takebe, N. et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nature Rev. Clin. Oncol. 12, 445-464 (2015).
42. West, N. R., Murray, J. I. & Watson, P. H. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 33, 1485-1494 (2014).
43. Schonberg, D. L. et al. Preferential iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell 28, 441-455 (2015).
44. Pinnix, Z. K. et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med. 2, 43ra56 (2010).
45. Yamane, K. et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell 25, 801-812 (2007).
46. Yamamoto, S. et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell 25, 762-777 (2014).
47. Greer, E. L. & Shi, Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 13, 343-357 (2012).
48. Shen, L. et al. Genome-wide analysis reveals TET-and TDG-dependent 5-methylcytosine oxidation dynamics. Cell 153, 692-706 (2013).
49. Tsai, Y.-P. et al. TET1 regulates hypoxia-induced epithelial-mesenchymal transition by acting as a co-activator. Genome Biol. 15, 513 (2014).
50. Hu, X. et al. Tet and TDG mediate DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell reprogramming. Cell Stem Cell 14, 512-522 (2014).